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Diagnostic assays for persistent chlamydial infection are much needed to conduct
high-quality, large-scale studies investigating the persistent state in vivo, its disease
associations and the response to therapy. Yet in most studies the distinction between
acute and persistent infection is based on the interpretation of the data obtained by
the assays developed to diagnose acute infections or on complex assays available for
research only and/or difficult to establish for clinical use. Novel biomarkers for detection of
persistent chlamydial infection are urgently needed. Chlamydial whole genome proteome
arrays are now available and they can identify chlamydial antigens that are differentially
expressed between acute infection and persistent infection. Utilizing these data will
lead to the development of novel diagnostic assays. Carefully selected specimens from
well-studied patient populations are clearly needed in the process of translating the
proteomic data into assays useful for clinical practice. Before such antigens are identified
and validated assays become available, we face a challenge of deciding whether the
persistent infection truly induced appearance of the proposed marker or do we just
base our diagnosis of persistent infection on the presence of the suggested markers.
Consequently, we must bear this in mind when interpreting the available data.
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BACKGROUND
The clinical spectrum of human chlamydial infections includes
clinically unapparent infections, acute symptomatic infections as
well as persistent infections (defined as the presence of viable
but non-cultivable chlamydiae). Persistent Chlamydia psittaci
infection in cultured cells was described over 30 years ago
(Moulder et al., 1980). Similar continuous infection models
in cell lines without external induction have later been estab-
lished for Chlamydia trachomatis (Lee and Moulder, 1981) and
Chlamydia pneumoniae (Kutlin et al., 1999). In cultured cells, per-
sistent infection can also be induced by external factors, including
amino acid starvation, interferon-γ-induced tryptophan depri-
vation, iron chelation, tobacco smoke and viral co-infection as
well as by exposure to antimicrobial agents (for review, see Beatty
et al., 1994; Hogan et al., 2003). Furthermore, chlamydial infec-
tion in monocyte/macrophage cultures has the appearance of a
persistent infection (Mannonen et al., 2004, 2011). The presence
of large, pleomorphic reticulate bodies, named aberrant bodies,
inhibition of binary fission and inability of the aberrant bodies to
transform into infectious elementary bodies, characterize in vitro
persistence. Transcriptomic and proteomic analyses have con-
firmed that there is continued genome replication and messenger
RNA synthesis in the aberrant bodies, but altered cell division
(Nicholson et al., 2003; Mäurer et al., 2007).
Although the persistence of C. trachomatis and C. pneumo-
niae in vitro is rather well studied, much less is known, if
the features typical of in vitro persistent infection also charac-
terize persistent experimental or human chlamydial infection.
Recently, aberrant bodies were shown to develop in uterine horns
of mice infected with C. muridarum and treated with amox-
icillin (Phillips Campbell et al., 2012). Amoxicillin treatment
also reduced vaginal shedding of infectious EB while accumula-
tion of the chlamydial pre—16s rRNA was unaffected (Phillips
Campbell et al., 2012). This indicates that chlamydial persistent
infection can occur in vivo. As the bacteria become dormant and
persistent, they are suggested to evade host protective immune
responses, although the immune system can be still be stim-
ulated at low-level which may contribute to the development
of immune-mediated pathology (Beatty et al., 1994; Phillips
Campbell et al., 2012). Follow-up studies on human ocular and
recurrent genital C. trachomatis infections have shown features
common to persistent state, such as the frequent detection of
chlamydial nucleic acid while the organisms can infrequently be
cultured (Hudson et al., 1992; Dean et al., 2000). Clinical data
also suggests that C. pneumoniae may persist for months after
the initial infection (Grayston, 1992), and persistent lung infec-
tions despite of antimicrobial therapy have been reported (Falck
et al., 1996; Miyashita et al., 2002). C. trachomatis DNA has been
demonstrated by in situ hybridization in the fallopian tube tis-
sue from infertile women (Campbell et al., 1993; Barlow et al.,
2001). Significantly elevated IgA antibody levels considered sug-
gestive of persistent infection were found among the currently or
formerly smoking men compared to their non-smoking co-twins
(von Hertzen et al., 1998). Moreover, electron micrographs have
demonstrated different stages of C. pneumoniae in atheroscle-
rotic plaques (Spagnoli et al., 2007; Bobryshev et al., 2008), and
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antigens whose expression is up regulated during the persistent
state of C. pneumoniae have been detected in human atheromas
(Borel et al., 2012).
In vitro, chlamydial persistence has also been characterized at
molecular level. Although the phenotype of persistent infections
is rather similar irrespective of the inducer, the transcriptional
studies on persistent chlamydial infection have failed to reveal a
profile common for differentmodels (Hogan et al., 2003; Goellner
et al., 2006; Klos et al., 2009). This might reflect variation in
the experimental systems but it could also indicate variability
of the mechanisms acting in the different models of persistent
infection. Based on the relative chlamydial rRNA transcript levels
in persistently infected monocytes and actively growing epithe-
lial cells, the metabolic rate of C. trachomatis in monocytes
is lower than in the cells where C. trachomatis grows produc-
tively (Gérard et al., 2002). When chlamydial transcription and
translation were analyzed upon IFN-γ exposure in the epithe-
lial cells, the global chlamydial transcription was shown to be
up regulated but the protein synthesis was reduced suggesting
uncoupling of transcription and translation (Ouellette et al.,
2006). Although this phenomenon can represent a successful sur-
vival strategy for Chlamydiae, it might also mean less potential
chlamydia-derived biomarkers available for detection of the per-
sistent stage. Nevertheless, quantitative proteomic profiling of the
persistent and the acute chlamydial infection to identify differ-
entially expressed proteins represents a possibility for providing
diagnostic targets for the persistent infection. The proteins asso-
ciated with persistent infection could be useful as biomarkers for
the diagnosis, as therapeutic targets, and ultimately as response-
to-therapy markers. However, the initial studies in this area also
failed to reveal a common profile between different models and
different chlamydial species (Mukhopadhyay et al., 2006). Upon
exposure to IFN-γ, the presence of aberrant C. trachomatis forms
was associated with down-regulation of the outer membrane pro-
teins (OmpA, OmpB) in cell culture, while the expression of
chlamydial GroEL was unaltered (Beatty et al., 1993). Attempts
to characterize the protein composition of C. pneumoniae dur-
ing persistent stage have shown a marked up-regulation of OmpA
and GroEL upon IFN-γ exposure, whereas no significant decrease
in bacterial protein expression was observed (Molestina et al.,
2002). On the other hand, upon iron limitation unchanged levels
of C. pneumoniae OmpA and GroEL were observed, while alto-
gether twenty differentially regulated chlamydial proteins were
observed (Wehrl et al., 2004). Many of these proteins remained
unidentified.
A serum-based assay would be most desirable for the diag-
nosis of persistent infection. Serum samples are relatively easily
obtained whereas tissue samples from the site of persistent infec-
tion often require invasive sampling and are thus not readily
available. The recent studies on serology during persistent infec-
tion suggest that the antibody response could indeed reflect
altered protein of chlamydial expression in vivo but this needs fur-
ther studies (see below). Despite of all the recent discoveries, the
development of diagnostic tests for persistent infections remains
challenging.
In this minireview, diagnostic options of human persistent
chlamydial infection will be discussed (see also Table 1).
CULTURE
By definition, the detection of persistent chlamydial infection
(defined as the presence of viable but non-cultivable chlamydiae)
by culture is not possible. Culture has, however, been success-
fully used in the early studies on persistency. During experimental
mouse infection, Chlamydiae are able to remain in tissues after
cessation of shedding and the infection can be reactivated by
cortisone treatment (Yang et al., 1983; Malinverni et al., 1995;
Laitinen et al., 1996; Cotter et al., 1997). In these studies, mice
were infected and the infection was followed by culture. After the
clearance of a culture-positive infection, cortisone was adminis-
tered. This obviously activated persistent Chlamydiae, as infec-
tious bacteria could again be recovered, at least in a proportion
of mice.
Although the persistent state is still rather poorly defined
in vivo, this observation is of potential significance in human
persistent infection: Corticosteroids are included e.g., in the
treatment of patients with exacerbations of asthma and chronic
obstructive bronchitis, conditions associated with persistent
C. pneumoniae infection (Hahn et al., 1991), and the steroid ther-
apy could reactive infection. If this takes place in vivo, it might
aggravate infection, and enhance transmission but on the other
hand, it might make the bacteria more sensitive to action of
antibiotics. There is, however, little, if any clinical data to sup-
port this. Partly this could be due to issues related to proper
sample collection, as the persistent chlamydial forms can local-
ize in tissues, and not necessarily in the mucosal surface available
for swabbing (Cappuccio et al., 1994). Recently, biologic response
modifiers have been introduced to the treatment of inflamma-
tory diseases. Whether these new therapies could also reactivate
persistent chlamydial infection, remains to be studied.
ANTIGEN DETECTION
To circumvent limitations of the culture, immunological anti-
gen detection methods, such as enzyme immunoassay and direct
immunofluorescence staining were developed for diagnosis of
chlamydial infections. Theoretically, detection of a chlamydial
antigen in clinical specimens could serve as a diagnostic test
for persistent infection. However, the general notion is that
the detection of chlamydial EB in mucosal smears indicates
presence of a current C. trachomatis (Havlichek et al., 1990)
or C. pneumoniae (Grayston et al., 1986) infection. It would
obviously require more invasive sampling than swabbing of
the mucosa to demonstrate the hallmarks of persistent infec-
tion, the aberrant bodies, at the site of infection. Moreover,
the amount of aberrant bodies in the specimen is likely to
be very small and reagents to visualize them are not readily
available.
For research purposes, the detection of chlamydial antigen(s)
by immunocytochemistry (ICC) in tissues has proven useful and
ICC has assisted studies on clinical features of persistent infec-
tions, including post infectious tubal infertility (Patton et al.,
1994) and atherosclerosis (Kuo and Campbell, 2000). Instead,
detection of a soluble circulating chlamydial antigen could repre-
sent a practical tool in diagnosis. The quantification of chlamydial
lipopolysaccharide (cLPS) in human sera by enzyme immunoas-
say represents a potential marker for persistent infection (Tiirola
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Table 1 | Potential biomarkers of persistent human chlamydial infection.
Marker Chlamydial
species
Remarks Condition References
Chlamydial LPS-containing
immune complexes in serum
C. pneumoniae Technically demanding
assay
Acute myocardial infarction Leinonen et al., 1990
Chronic coronary heart disease Linnanmäki et al., 1993
COPD Von Hertzen et al., 1997
Stroke Tarnacka et al., 2002
Chlamydial LPS in
tissues/serum
C. pneumoniae Technically demanding
assay
Atherosclerosis Kuo et al., 1993; Vikatmaa et al., 2010
Acute coronary event Tiirola et al., 2007
Novel cardiovascular event Pesonen et al., 2009a,b
Elevated IgG and IgA antibody C. pneumonia Asthma Von Hertzen et al., 1997; Hahn et al.,
2000
C. trachomatis Infertility Sarov et al., 1986
IgA antibody response to whole
bacteria
C. pneumoniae Interlaboratory variation in
MIF
Acute coronary syndrome Huittinen et al., 2003; Miya et al., 2004
Asthma Sävykoski et al., 2004; Von Hertzen
et al., 1997; Hahn and Saikku, 1995
Predictor of treatment
response
Hahn et al., 2006
Increased intima-media
thickness in children
Volanen et al., 2006
IgE antibody response C. pneumoniae Immunoblot format Asthma, severity of asthma Emre et al., 1995; Hahn et al., 2000,
2012
Chlamydial DNA in mucosal
swabs or tissues
C. pneumoniae Not detected in veins or in
the vessel wall in the
absence of pathology
Atherosclerosis Kuo et al., 1993; Rosenfeld and
Campbell, 2011
COPD Von Hertzen et al., 1997
C. trachomatis Trachoma Mabey and Solomon, 2003
Tubal factor infertility Campbell et al., 1993; Barlow et al., 2001
Chlamydial rRNA in tissues C. trachomatis Denotes presence of
metabolically active
bacteria
Reactive arthritis Gérard et al., 1998
Trachoma Burton et al., 2006
Antibody to GroEL (CPn0134 or
CT110)
C. pneumoniae Autoimmunity manifested
as antibody to human
Hsp60 contributes to
pathogeneses
Asthma Huittinen et al., 2001
Coronary heart disease Huittinen et al., 2002; Mahdi et al., 2002;
Biasucci et al., 2003; Pesonen et al.,
2009a
C. trachomatis Trachoma Skwor et al., 2010
Subfertility Karinen et al., 2004
Infertility Linhares and Witkin, 2010
Tubal factor infertility Tiitinen et al., 2006; Bunk et al., 2008;
Budrys et al., 2012
Antibody to CT858 C. trachomatis Trachomatous trichiasis Skwor et al., 2010
Seroresponse to a panel
consisting of CT110, CT376,
CT557, CT443 and absence of
response to CT875, CT147
C. trachomatis Some antigens also
recognized by sera from
acute infection Remains to
be confirmed in larger
settings
Tubal factor infertility Budrys et al., 2012
Seroresponse to a panel
consisting of antigens CPn0695,
CPn0134, CPn0626CPn0702,
CPn 449/450, CPn 0854,CPn
0963, CPn1016
C. pneumoniae Remains to be confirmed
in larger settings
Presence of C. pneumoniae
DNA in the coronary artery or
in the PBMC
Bunk et al., 2008
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et al., 2006). Chlamydial LPS was detected in serum during acute
coronary events and its presence correlated with the C-reactive
protein levels (Tiirola et al., 2007). Moreover, the circulating
cLPS was associated with a new cardiovascular event during
the follow-up period (Pesonen et al., 2009b). Also, circulating
chlamydial LPS-containing immune complexes have been sug-
gested to be important in the pathogenesis and serve as markers
of persistent infection (Leinonen et al., 1990; Linnanmäki et al.,
1993), but the assay is technically rather demanding and it has
only been used in research.
NUCLEIC ACID AMPLIFICATION
Nucleic acid amplification test kits (NAATs) have revolutionized
the diagnosis of acute C. trachomatis infections offering high sen-
sitivity and specificity. The NAATs, including polymerase chain
reaction (PCR), are also well suitable for the detection of persis-
tent chlamydial infection, when lower quantities of Chlamydiae
are produced challenging the sensitivity of the detection method.
Indeed, the use of amplification technologies and culture has
given us clues that persistent, non-cultivable chlamydial infec-
tions do occur in vivo. Trachoma in children can often be diag-
nosed by culture, whereas the agent can no longer been cultured
in the blinding stage (Grayston andWang, 1975). Similarly,C. tra-
chomatis can be cultured in acute lower genital tract infections,
while culture rarely succeeds in upper genital infections, includ-
ing tubal factor infertility, although C. trachomatis DNA can be
amplified by PCR (Brunham et al., 1985). The mere demonstra-
tion of bacterial DNA does not, however, indicate viability, but
could be related to the higher sensitivity of the PCRmethod per se.
Identification of chlamydial rRNA primary transcripts indicates
that the bacteria are metabolically active (Gérard et al., 1997).
Indeed, in the synovial samples from patients with reactive arthri-
tis primary rRNA transcripts and mRNA from chlamydial genes
were present (Gérard et al., 1998).
PCR with C. pneumoniae-specific primers has played an
important role in confirming the presence of DNA from these
bacteria in atheromas and circulating blood cells. In combi-
nation with serology and ICC, the PCR has been a valuable
tool in the studies confirming the link between atherosclerosis
and infections, especially with persistent C. pneumoniae infec-
tion (Campbell and Kuo, 2004; Rosenfeld and Campbell, 2011).
Current data supports that this condition represents a persistent
infection: Ex vivo culture of C. pneumoniae from atherosclerosis is
rare, while PCR can frequently detect chlamydial DNA in diseased
tissues (Campbell and Kuo, 2004). Studies in mice show that the
presence of C. pneumoniae DNA in tissues is an indicator of prior
infection, and when the bacteria are not cultivable it is suggestive
of persistence, as DNA in the non-viable bacteria degrades fast
in vivo (Moazed et al., 1998).
SEROLOGY
Serology has been a valuable tool in epidemiological studies,
in studies describing clinical spectrum of chlamydial infections,
including persistent infection, and in research. Serology is also
commonly used to diagnose acute C. pneumoniae infections in
clinical practice while its value in the laboratory diagnosis of
acute C. trachomatis infections is slim. It may, however, prove
helpful when studying complications of the acute phase (e.g.,
reactive arthritis) andmanifestations of persistent infections (e.g.,
tubal factor infertility). Microimmunofluorescence (MIF) test
using fixed purified whole bacteria as antigen has been consid-
ered a golden standard of chlamydial serology, but automatable
enzyme immunoassays (EIA) have taken root in clinical labo-
ratories, partly because the MIF can suffer from subjectivity in
interpretation and interlaboratory variation (Peeling et al., 2000).
TheMIF andmost EIAs detect antibody response against proteins
on the surface of Chlamydiae, and established guidelines on the
diagnostic criteria for acute C. pneumoniae infections are avail-
able: IgM appears in the first infection in 3 weeks, IgG in 6–8
weeks, and if adequately timed paired sera are available, a≥4-fold
IgG titer rise can be seen upon infection and reinfection (Wang
and Grayston, 1986).
Despite of considerable efforts, persistent infections are diffi-
cult to diagnose, and no widely accepted serological criteria for
persistent infection exist at present. IgG antibody can persist long
after the acute phase (Puolakkainen et al., 1986; Paldanius et al.,
2005), and only reflects (previous) exposure to the organisms.
Some markers have yet been brought forward. Elevated IgE levels
are almost always associated with asthma, a proposed manifes-
tation of persistent C. pneumoniae infection, but the inducing
factor for the IgE response has largely remained unknown. In a
recent case-control study, C. pneumoniae-specific IgE antibody
response was strongly associated with asthma and with sever-
ity of asthma in adults (Hahn et al., 2012). IgA antibodies are
naturally short-lived with a half-life of 5–6 days. Consistently
present/elevated C. pneumoniae IgA antibody titers (Saikku et al.,
1992), and elevated serum C. pneumoniae IgA and IgG antibodies
together with elevated C-reactive protein (Huittinen et al., 2003;
Miya et al., 2004; Sävykoski et al., 2004) have been proposed as
serological markers of persistent C. pneumoniae infection. IgA
response could also be a predictor of treatment response (Hahn
et al., 2006). Additionally, an association between C. pneumoniae
IgA and human Hsp60 antibodies noted in patients with risk of
coronary events (Huittinen et al., 2002) suggests that antibodies
to human Hsp60 could be induced by bacterial GroEL (C. pneu-
moniae Hsp60 homolog, CPn0134) during persistent infection.
Likewise, enhanced antibody response to C. trachomatis EB and
chlamydial GroEL (C. trachomatis Hsp60 homolog, CT110) pro-
tein is associated with trachoma (Skwor et al., 2010) subfertility
(Karinen et al., 2004), infertility, especially tubal factor infertility,
a manifestation of persistent C. trachomatis infection (Toye et al.,
1993; Witkin et al., 1998; Tiitinen et al., 2006).
Although the performance of the serological assays using
whole bacteria as antigen and developed for the detection of acute
infection might not be perfect, they have been valuable in epi-
demiological studies and when patient populations with a given
condition have been studied. Moreover, the expanding clinical
spectrum of chlamydial diseases, including those associated with
persistent infection, was initially based on the findings obtained
with the traditional but specific chlamydial serology. The antibod-
ies recognized by the MIF are directed against the surface proteins
of the chlamydial EB. OmpA (major outermembrane protein) is a
dominant immunogen inC. trachomatis, but the (C. pneumoniae)
proteins contributing to the MIF reactivity have largely remained
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unknown (Bunk et al., 2008). Proteomic analyses of chlamydial
infection have revealed that a part of the surface proteins are
more frequently and a part of them less frequently expressed
during persistent than acute infection. Consequently, the MIF
test as well as the EIAs using whole bacterial antigen might not
be able to adequately discriminate between acute and persistent
infections (Bunk et al., 2008). In support of this observation,
reactivity of the sera from individuals with persistent infection in
the MIF tests is necessarily not reflected by the reactivity of these
sera with differentially expressed antigens, including chlamydial
GroEL (Huhtinen et al., 2001; Bunk et al., 2008).
Proteomic profiling of chlamydial infection may enable the
development of more precise serological assays that could bet-
ter differentiate responses related to acute infection, cured past
infection (serological scar) and persistent infection. The history
and clinical status of the patients donating the serum specimens
must be characterized appropriately. This is not always possible
and straightforward, and may need invasive and extensive exam-
inations. To identify antibody response patterns associated with
persistent C. pneumoniae infection, Bunk et al. (2008) applied
a proteomic approach with 2D-gel electrophoresis combined
with immunoblotting. Using serum specimens from patients
with probable persistent infection, based on the presence of
C. pneumoniae DNA in their coronary arteries or in their PBMC,
and blood donors without such markers of persistent infection,
the researchers could identify a differential response against 12
C. pneumoniae antigens, including both increased and decreased
reactivity (Bunk et al., 2008). Sera from the PCR-positive indi-
viduals reacted more intensely with C. pneumoniae CPn0695
(OmpA) and CPn0134 (GroEL) [and also with 6 other anti-
gens, CPn0626 (RpoA), CPn0702 (YscC), CPn449/450 (Pmp10),
CPn0854 (PorB), CPn0963 (Pmp21), and CPn1016 (Cpaf)] than
sera from controls. The observed antibody response pattern was
in accordance with the earlier mentioned in vitro proteomic stud-
ies showing higher and lower seroreactivity toward the proteins
that were shown to be up-regulated and down-regulated, respec-
tively, during IFN-γ-mediated persistence (Molestina et al., 2002;
Mukhopadhyay et al., 2006). A recent description of a C. pneu-
moniae ORFeome library covering 99% of the 1052 the ORFs
of C. pneumoniae provides an additional novel tool for studying
the seroresponses during persistent phase in-depth (Maier et al.,
2012).
To identify novel C. trachomatis proteins or protein com-
binations associated with different stages of infection, a high-
resolution whole genome scale protein array (Wang et al.,
2010) has been used to profile serological responses. Sera from
patients with tubal factor infertility (TFI) and their controls
recognized many C. trachomatis proteins (Wang et al., 2010).
Comparison of the antibody profiles revealed that the sera from
TFI patients preferentially recognized 30 C. trachomatis proteins.
Those included CT110 (GroEL; 71% of sera reacted with this
protein) confirming the earlier findings that response to the
Hsp60 homolog is associated with TFI. In this study, no sin-
gle antigen yielded 100% specificity and >50% sensitivity for
detection of TFI, whereas a combination of CT443 (omcB) and
CT381 (arginine binding protein) antigens yielded the highest
detection sensitivity (68%) for chlamydial TFI while maintaining
100% specificity (Rodgers et al., 2011). However, also C. tra-
chomatis antibody-positive individuals with acute C. trachoma-
tis infection frequently reacted with GroEL, and diminished
the value of this antigen as a marker of persistent infection.
Subsequently, panels of C. trachomatis antigens that could predict
tubal pathology and acute infection have been suggested. Using
the same high-resolution approach, reactivity with four proteins
[CT110 (GroEL), CT376 (malate dehydrogenase), CT557 (dihy-
drolipoamide hydrolase), and CT443 (OmcB)] could distin-
guish women with TFI from fertile women with a sensitivity
of 63% and specificity of 100%. Reactivity with a combina-
tion of two C. trachomatis antigens (CT875 and CT147, both
coding for hypothetical proteins) could discriminate between
women with acute infection and those with TFI (Budrys et al.,
2012) enabling sequential screening to identify patients with these
conditions.
CONCLUSION
A serum-based assay (either for antibody detection, antigen
detection or nucleic acid amplification) would be desirable for
the detection of persistent infection. Serum samples are relatively
easily obtained whereas tissue samples from the site of persis-
tent infection are not readily available. The above-mentioned
recent studies utilizing proteomics and bacterial genome wide
approaches by Bunk et al. (2008), Rodgers et al. (2011) and
Budrys et al. (2012) indicate that chlamydial serology can bemade
more precise and refined. These studies also demonstrate the first
evidence of differential serological response as a function of the
infection status. Discrimination of antibody response related to
persistent infection from that related to acute infection and from
a serological scar is important and clinically relevant, and these
promising approaches wait to be confirmed in studies with larger
populations.
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